{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:37:04Z","timestamp":1753893424211,"version":"3.41.2"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T00:00:00Z","timestamp":1673222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["por-journal.com"],"crossmark-restriction":true},"short-container-title":["Pathol. Oncol. Res."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Extranodal natural killer\/T-cell lymphoma (ENKL) is a rare subtype of mature T and natural killer cell lymphomas associated with Epstein-Barr virus.<\/jats:p><jats:p><jats:bold>Case:<\/jats:bold> A 20-year-old presented with severe neurological symptoms and was diagnosed with stage IV ENKL, nasal type, with CNS involvement. Overall, the patient received nine treatment lines, including chemotherapy, craniospinal irradiation, allogeneic stem cell transplant (alloSCT), donor lymphocyte infusions, and novel agents (Nivolumab, Daratumumab, Thalidomide, Lenalidomide, virus-specific T cells) combined with intrathecal chemotherapy. The treatment effect was evaluated in both blood and CSF (cerebrospinal fluid). First-line SMILE chemotherapy resulted in systemic and CNS remission. Later Cytarabine-based chemotherapy and Daratumumab combination helped to reinduce remission before alloSCT.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> We show that efficacy monitoring should include both blood and CSF analysis. High-dose Cytarabine-based chemotherapy in combination with Daratumumab and intrathecal chemotherapy may be considered as salvage CNS-directed therapies. We add to existing limited data that Daratumumab penetrates the blood-brain barrier.<\/jats:p>","DOI":"10.3389\/pore.2022.1610866","type":"journal-article","created":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T04:11:31Z","timestamp":1673237491000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case report: Relapsed\/refractory extranodal natural killer\/T-cell lymphoma nasal type with extensive central nervous system involvement"],"prefix":"10.3389","volume":"28","author":[{"given":"Aust\u0117ja","family":"Dapkevi\u010di\u016bt\u0117-Purlien\u0117","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vytautas","family":"Augustinavi\u010dius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrius","family":"\u017du\u010denka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1182\/blood-2017-12-791418","article-title":"Advances in the treatment of extranodal NK\/T-cell lymphoma, nasal type [Internet]","volume":"131131","author":"Yamaguchi","year":"2018","journal-title":"Blood."},{"key":"B2","first-page":"98","article-title":"Current treatment approaches for NK\/T-cell lymphoma","volume-title":"J Clin Exp Hematop","author":"Yamaguchi","year":""},{"key":"B3","first-page":"e16747","article-title":"Extranodal natural killer\/T-cell lymphoma nasal type with central nervous system involvement mimicked tuberculous meningitis: A case report","volume-title":"Medicine (Baltimore)","author":"Yang","year":""},{"key":"B4","first-page":"993","article-title":"Extranodal nasal NK\/T-cell lymphoma with dissemination to the central nervous system: A case report","volume":"54","author":"Romero-Guadarrama","year":"2010","journal-title":"Acta Cytol"},{"key":"B5","first-page":"861","article-title":"Diagnosis and management of extranodal NK\/T cell lymphoma nasal type","volume-title":"Expert Rev Hematol","author":"Tse","year":""},{"key":"B6","first-page":"107","article-title":"Intrathecal donor lymphocyte infusion for isolated leukemia relapse in the central nervous system following allogeneic stem cell transplantation: A case report and literature review","volume-title":"Int J Hematol","author":"Yanagisawa","year":""},{"key":"B7","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1038\/s41409-018-0409-9","article-title":"Treatment of Epstein\u2013Barr virus associated central nervous system diseases after allogeneic hematopoietic stem cell transplantation with intrathecal donor lymphocyte infusion","volume":"54","author":"Zhao","year":"2019","journal-title":"Bone Marrow Transpl"},{"key":"B8","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.beha.2018.07.002","article-title":"Extranodal NK\/T-cell lymphoma: Updates in biology and management strategies [Internet]","volume":"3131","author":"Yamaguchi","year":"2018","journal-title":"Best Pract Res Clin Haematol"},{"key":"B9","first-page":"193","article-title":"PD1 blockade with low-dose nivolumab in NK\/T cell lymphoma failing l-asparaginase: Efficacy and safety [internet]","volume-title":"Ann Hematol","author":"Chan","year":""},{"key":"B10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13045-018-0559-7","article-title":"Activity of pembrolizumab in relapsed\/refractory NK\/T-cell lymphoma","volume":"11","author":"Li","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1182\/blood-2016-12-756841","article-title":"PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK\/T-cell lymphoma failing L-asparaginase","volume":"129","author":"Kwong","year":"2017","journal-title":"Blood."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e4446","DOI":"10.7759\/cureus.4446","article-title":"Efficacy of pembrolizumab and nivolumab in crossing the blood brain barrier","volume":"11","author":"Abid","year":"2019","journal-title":"Cureus"},{"key":"B13","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1186\/s12885-019-5741-y","article-title":"Intracranial antitumor responses of nivolumab and ipilimumab: A pharmacodynamic and pharmacokinetic perspective, a scoping systematic review","volume":"19","author":"Van Bussel","year":"2019","journal-title":"BMC Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/ajco.13375","article-title":"Neurological immune-related adverse events associated with immune checkpoint inhibitors: A review of the literature","volume":"16","author":"Fan","year":"2020","journal-title":"Asia Pac J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1182\/blood-2018-99-111885","article-title":"Daratumumab monotherapy for patients with relapsed or refractory (R\/R) natural killer\/T-cell lymphoma (NKTCL), nasal type: An open-label, single-arm, multicenter phase 2 study","volume":"132","author":"Kim","year":"2018","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","first-page":"3970169","DOI":"10.1155\/2018\/3970169","article-title":"Multiple myeloma of the central nervous system: 13 cases and review of the literature","volume":"2018","author":"Varga","year":"2018","journal-title":"J Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1016\/S0140-6736(09)61416-1","article-title":"High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: A randomised phase 2 trial","volume":"374","author":"Ferreri","year":"2009","journal-title":"Lancet"},{"key":"B18","first-page":"33","article-title":"Molecular pathogenic pathways in extranodal NK\/T cell lymphoma","volume-title":"J Hematol Oncol","author":"De Mel","year":""},{"key":"B19","first-page":"695","article-title":"Thalidomide plus chemotherapy exhibit enhanced efficacy in the clinical treatment of T-cell non-hodgkin\u2019s lymphoma: A prospective study of 46 cases","volume-title":"Mol Clin Oncol","author":"Wu","year":""},{"key":"B20","first-page":"1036","article-title":"First-line combination of GELOX followed by radiation therapy for patients with stage IE\/IIE ENKTL: An updated analysis with long-term follow-up","volume-title":"Oncol Lett","author":"Wang","year":""},{"key":"B21","doi-asserted-by":"publisher","first-page":"00366","DOI":"10.15406\/jcpcr.2018.09.00366","article-title":"Locally advanced angiocentric nk\/t cell lymphoma of nasal cavity","volume":"9","author":"Kumar","year":"2018","journal-title":"J Cancer Prev Curr Res"},{"key":"B22","first-page":"943","article-title":"Plasma and cerebrospinal fluid pharmacokinetics of thalidomide and lenalidomide in nonhuman primates","volume-title":"Cancer Chemother Pharmacol","author":"Muscal","year":""},{"key":"B23","first-page":"1595","article-title":"Phase 1 investigation of lenalidomide\/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma","volume-title":"Blood Adv","author":"Rubenstein","year":""},{"key":"B24","first-page":"2351","article-title":"EBV\/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation","volume-title":"Blood","author":"McLaughlin","year":""},{"key":"B25","first-page":"1443","article-title":"Allogeneic BK virus\u2013specific T cells for progressive multifocal leukoencephalopathy","volume-title":"N Engl J Med","author":"Muftuoglu","year":""},{"key":"B26","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/sj.bmt.1702116","article-title":"Extramedullary relapse in the so-called \u201csanctuary\u201d sites for chemotherapy after donor lymphocyte infusion","volume":"25","author":"Seo","year":"2000","journal-title":"Bone Marrow Transplant"}],"container-title":["Pathology and Oncology Research"],"original-title":[],"link":[{"URL":"https:\/\/www.por-journal.com\/articles\/10.3389\/pore.2022.1610866\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T04:11:41Z","timestamp":1673237501000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.por-journal.com\/articles\/10.3389\/pore.2022.1610866\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,9]]},"references-count":26,"alternative-id":["10.3389\/pore.2022.1610866"],"URL":"https:\/\/doi.org\/10.3389\/pore.2022.1610866","relation":{},"ISSN":["1532-2807"],"issn-type":[{"type":"electronic","value":"1532-2807"}],"subject":[],"published":{"date-parts":[[2023,1,9]]},"article-number":"1610866"}}